Leadership & Pay ·
BetterLife Pharma appoints Charles Duncan as director and Audit Committee chair, grants him 625,000 stock options
BETRFBetterLife Pharma Inc.
BetterLife Pharma Inc. appointed Charles Duncan, PhD, as a director and Chair of the Audit Committee on August 31, 2026. The company granted Dr. Duncan stock options to purchase 500,000 common shares at an exercise price of $0.285, vesting quarterly over 24 months, plus an additional 125,000 options with a three-month vesting period. Between September 1 and 10, 2026, the company received gross proceeds of $127,500 from the exercise of 850,000 share purchase warrants at $0.15 per share. Proceeds will fund ongoing development of BETR-001 and working capital needs. The company also approved its Amended and Restated Long-term Incentive Plan on August 27, 2026. BetterLife Pharma Inc. is an emerging biotechnology company developing BETR-001 for the treatment of migraine and headache disorders.